Safety of Agaricus blazei Murill in Cancer Patients
Author Information
Author(s): Ohno Satoshi, Sumiyoshi Yoshiteru, Hashine Katsuyoshi, Shirato Akitomi, Kyo Satoru, Inoue Masaki
Primary Institution: Kanazawa University
Hypothesis
Does Agaricus blazei Murill cause adverse effects in cancer patients in remission?
Conclusion
Agaricus blazei Murill is generally safe for cancer patients in remission, with few adverse effects observed.
Supporting Evidence
- 12% of patients experienced adverse events, mostly digestive issues.
- None of the adverse events were dose-dependent.
- Most laboratory parameters remained normal throughout the study.
Takeaway
This study looked at a mushroom supplement and found that most people can take it without getting sick, but a few had some tummy troubles.
Methodology
Cancer patients took different doses of Agaricus blazei Murill for 6 months, and their health was monitored for adverse effects.
Potential Biases
Potential bias due to the small sample size and lack of a control group.
Limitations
The study was limited to 78 patients and may not represent all cancer patients.
Participant Demographics
78 patients (46 male, 32 female) with a mean age of 65.6 years.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website